Company Of The Day: Johnson & Johnson
What?
Johnson & Johnson (NYSE:JNJ) reported a mixed Q4 with revenue of $24.8 billion falling short of $25.3 billion consensus estimate but its earnings of $2.13, on a per share and adjusted basis, were a cent above the consensus estimate of $2.12.
Why?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
- Should You Pick Johnson & Johnson Stock After A 6% Fall In A Month Despite Upbeat Q3?
- What’s Happening With Johnson & Johnson Stock?
- Johnson & Johnson Poised For A Muted Q2?
- Cross-Sector Comparison: Is Caterpillar Stock A Better Pick Over J&J?
Growth was driven by the stronger performance of the pharmaceuticals business, while its medical devices and consumer healthcare business faced headwinds due to the spread of the Omicron.
So What?
JNJ stock rose by about 3% in Tuesday’s trading. We estimate Johnson & Johnson valuation at $202 per share, about 20% ahead of the current market price. This represents a forward P/EBITDA multiple of 19.1 for the company based on our forecast for Johnson & Johnson EBITDA.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
Returns | Jan 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
JNJ Return | -2% | -2% | 45% |
S&P 500 Return | -9% | -9% | 95% |
Trefis MS Portfolio Return | -13% | -13% | 243% |
[1] Month-to-date and year-to-date as of 1/26/2022
[2] Cumulative total returns since the end of 2016